

## ERRATA

Sr. No.	Page No.	Line/Line Number	Present Form	Changed Form
1	Title Page	First	ENHANCENENT	ENHANCEMENT
2	25	22(Point 10)	Finally <i>in vivo</i> _____its formulations.	Finally <i>in vivo</i> _____its formulations. All experiments and protocol for this study was approved by Institutional Animal Ethics Committee, The M. S. University of Baroda, and are accordance with the committee for the purpose of control and supervision of the experiments on Animal, Ministry of Social Justice and Empowerment, Government of India.
3	89	Figure 3.1.2.2. Calibration Curve of Cilostazol in Mobile Phase at 254.0 nm	$Y=68.211X + 18.244$	$Y=68.211X - 18.244$
4	122	Figure 3.2.5.2.(b)	<p>—●— CME 2</p> <p>—■— CME 1</p>	<p>—●— CME 1</p> <p>—■— CME 2</p>
5	136	Figure 3.3.2.1.2(caption)	(○)β-CD; (♦) γ-CD	(♦)β-CD; (○) γ-CD
6	187	9	3 month	4 month
7	195	Table 3.3.5.3.	<b>83.72 ± 1.24</b>	<b>86.72 ± 1.24</b>
8	197	7	4.0 % to 12.0%	4.0% to 5.0%
9	214	15	Cilostazol	Tadalafil
10	219	28	μg	μL
11	220	19	0.9989	0.9966
12	221	14	Cilostazol	Tadalafil
13	245	12	Less	More
14	267	Figure 4.3.2.1.3(caption)	(*) HP-β-CD;(■) γ-CD	(■)HP- β-CD; (*)γ-CD
15	269 & 270	Figure 4.3.2.2.1., 4.3.2.2.2., 4.3.2.2.3. and 4.3.2.2.4.(caption)	* Physical Mixture	* Inclusion Complex

